<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">An Bras Dermatol</journal-id>
      <journal-id journal-id-type="iso-abbrev">An Bras Dermatol</journal-id>
      <journal-title-group>
        <journal-title>Anais Brasileiros de Dermatologia</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0365-0596</issn>
      <issn pub-type="epub">1806-4841</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Dermatologia</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">26312705</article-id>
      <article-id pub-id-type="pmc">4540539</article-id>
      <article-id pub-id-type="doi">10.1590/abd1806-4841.20153672</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>New drugs, new challenges for dermatologists: mucocutaneous ulcers
secondary to everolimus<xref ref-type="fn" rid="fn01">*</xref></article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Pasin</surname>
            <given-names>Victor Pavan</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Pereira</surname>
            <given-names>Amanda Regio</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
          <xref ref-type="corresp" rid="c01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>de Carvalho</surname>
            <given-names>Kalline Andrade</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>de Paiva</surname>
            <given-names>Jo&#xE3;o Marcos G&#xF3;es</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Enokihara</surname>
            <given-names>Milvia Maria Sim&#xF5;es e Silva</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Porro</surname>
            <given-names>Adriana Maria</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
        </contrib>
        <aff id="aff01"><label>1</label>Universidade Federal de S&#xE3;o Paulo (UNIFESP) - S&#xE3;o Paulo,
Brazil.</aff>
      </contrib-group>
      <author-notes>
        <corresp id="c01">MAILING ADDRESS: Amanda Regio Pereira, Rua Borges Lagoa, 508, Vila
Clementino, 04038-001 - S&#xE3;o Paulo - SP, Brazil. E-mail:
<email>amandaregiopereira@gmail.com</email></corresp>
        <fn fn-type="conflict">
          <p>Conflict of Interest: None.</p>
        </fn>
      </author-notes>
      <pub-date pub-type="epub-ppub">
        <season>May-Jun</season>
        <year>2015</year>
      </pub-date>
      <!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' -->
      <pub-date pub-type="ppub">
        <season>May-Jun</season>
        <year>2015</year>
      </pub-date>
      <volume>90</volume>
      <issue>3 Suppl 1</issue>
      <fpage>165</fpage>
      <lpage>167</lpage>
      <history>
        <date date-type="received">
          <day>04</day>
          <month>5</month>
          <year>2014</year>
        </date>
        <date date-type="accepted">
          <day>21</day>
          <month>5</month>
          <year>2014</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; 2015 by Anais Brasileiros de Dermatologia</copyright-statement>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">
          <license-p>This is an Open Access article distributed under the terms of the Creative
Commons Attribution Non-Commercial License which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the
original work is properly cited.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>Everolimus, a mammalian target of rapamycin inhibitor, is an emerging drug, which is
being increasingly applied in oncology and solid organ transplantation. Oral ulcers
are a frequent side effect associated with this immunosupressor. We report the case
of a renal transplant recipient who developed disfiguring oral and perianal ulcers
secondary to everolimus's toxicity. This is probably the first report of perianal
involvement. Dermatologists need to be aware of the potential mucocutaneous adverse
effects related to these new drugs that are becoming evermore common in our clinical
practice.</p>
      </abstract>
      <kwd-group>
        <kwd>Drug eruptions</kwd>
        <kwd>Immunosuppressive agents</kwd>
        <kwd>Ulcer</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro">
      <title>INTRODUCTION</title>
      <p>Mammalian target of rapamycin (mTOR) inhibitors, such as sirolimus and everolimus, are
emerging drugs, which are being increasingly applied in oncology and to help prevention
of rejection in solid organ transplant recipients<sup>.</sup><sup><xref rid="r01" ref-type="bibr">1</xref></sup> Oral ulcers have been reported as one of the most common
side effects of everolimus, affecting up to 70% of the patients treated with this drug,
leading to discontinuation of the therapy in many cases.<sup><xref rid="r02" ref-type="bibr">2</xref>,<xref rid="r03" ref-type="bibr">3</xref></sup> We report a case
of oral and perianal ulcers secondary to everolimus in a renal transplant recipient,
highlighting the severity of the lesions and the perianal involvement, which has not yet
been described in indexed medical journals.</p>
    </sec>
    <sec>
      <title>CASE REPORT</title>
      <p>A 38-year-old, female patient with end-stage renal disease of unknown etiology,
submitted to renal transplantation 3 months earlier, was hospitalized due to oral and
perianal ulcers she had suffered from over the preceding 14 days, which were resistant
to empirical therapy with oral acyclovir for 10 days (400mg every 8 hours). She had been
under immunosuppression with mycophenolate sodium (720mg daily), prednisone (30mg daily)
and everolimus (0.5 mg daily). The latter had been introduced 2 months earlier. The
patient was also diagnosed HIV positive 3 years before and presented with undetectable
viral load and a CD4 count of 308 cells/&#xB5;L upon admission, attributable to effective
antiretroviral therapy (ART) with zidovudine, lamivudine, atazanavir and ritonavir.
Dermatology consultation was requested by the nephrology team. On examination, two oral
ulcers were found on the superior lip and tongue. Both were deep and painful, and the
labial lesion was partially necrotic and quite disfiguring (<xref ref-type="fig" rid="f01">Figure 1</xref>). A deep, 2 cm-diameter ulcer in the perianal region was
also observed (<xref ref-type="fig" rid="f02">Figure 2</xref>). Histopathology of both
sites revealed chronic, non-specific ulcers, with scarce inflammatory lymphocytic
infiltrate (<xref ref-type="fig" rid="f03">Figure 3</xref>). Signs of viral infection
were absent on histology. Immunohistochemical detection of herpes simplex virus 1 and 2
and cytomegalovirus (CMV) resulted negative in these tissue samples. Antigenemia assay
and blood polymerase chain reaction for CMV were also negative. Everolimus blood level
was 11.7 ng/ml, which is above the target (3-8 ng/ml), also favoring the possibility of
drug-related toxicity, a diagnosis of exclusion in this case. The ulcers started to heal
after everolimus discontinuation. Complete reepithelization, though, was observed only
after 40 days. A residual deformity with aesthetic and functional impairment remained in
the superior lip, affecting movements such as suction (<xref ref-type="fig" rid="f04">Figure 4</xref>).</p>
      <fig id="f01" orientation="portrait" position="float">
        <label>FIGURE 1</label>
        <caption>
          <p>Deep and painful oral ulcers, partially necrotic and quite disfi guring</p>
        </caption>
        <graphic xlink:href="abd-90-03-s1-0165-g01"/>
      </fig>
      <fig id="f02" orientation="portrait" position="float">
        <label>FIGURE 2</label>
        <caption>
          <p>Deep, perianal ulcer, involving the skin and semi-mucous surface</p>
        </caption>
        <graphic xlink:href="abd-90-03-s1-0165-g02"/>
      </fig>
      <fig id="f03" orientation="portrait" position="float">
        <label>FIGURE 3</label>
        <caption>
          <p>Histopathological aspects: chronic non-specific ulcer, with scarce infl ammatory
lymphocytic infiltrate. Hematoxylin and eosin stain, 100x and 400x</p>
        </caption>
        <graphic xlink:href="abd-90-03-s1-0165-g03"/>
      </fig>
      <fig id="f04" orientation="portrait" position="float">
        <label>FIGURE 4</label>
        <caption>
          <p>Complete reepithelization 40 days after everolimus discontinuation. Residual
deformity in the superior lip, with aesthetic and functional impairment</p>
        </caption>
        <graphic xlink:href="abd-90-03-s1-0165-g04"/>
      </fig>
    </sec>
    <sec sec-type="discussion">
      <title>DISCUSSION</title>
      <p>mTOR inhibitor-associated stomatitis is a newly recognized and frequent drug-related
complication. It is a significant toxicity that leads to dose modifications, treatment
delay and interruption of antineoplastic and immunosuppressive regimens.<sup><xref rid="r02" ref-type="bibr">2</xref>,<xref rid="r04" ref-type="bibr">4</xref>,<xref rid="r05" ref-type="bibr">5</xref></sup> Lesions are usually described as painful,
long-lasting oval ulcerations that resemble aphthous or herpetic stomatitis.<sup><xref rid="r03" ref-type="bibr">3</xref>,<xref rid="r04" ref-type="bibr">4</xref>,<xref rid="r06" ref-type="bibr">6</xref></sup> Although its mechanisms remain unknown,
it seems that the frequency, duration and severity of this side effect are associated
with high doses and blood levels of everolimus.<sup><xref rid="r02" ref-type="bibr">2</xref>,<xref rid="r03" ref-type="bibr">3</xref>,<xref rid="r06" ref-type="bibr">6</xref>,<xref rid="r07" ref-type="bibr">7</xref></sup> Empiric treatments, such
as sodium bicarbonate-based mouthwash and oral fluconazole, appear to be useless and
managing the condition remains challenging.<sup><xref rid="r03" ref-type="bibr">3</xref></sup></p>
      <p>Some aspects in the case reported are unusual, namely the severity of ulcers that led to
tissue loss and drug discontinuation, and the perianal involvement, a location that has
not yet been mentioned in the indexed literature, according to extensive research in the
major online databases.</p>
      <p>Everolimus metabolism occurs predominantly by means of the hepatic cytochrome P450
system, resulting in multiple, possible pharmacological interactions.<sup><xref rid="r08" ref-type="bibr">8</xref></sup></p>
      <p>Blood levels above target that were detected in this patient could be attributed to drug
interaction, probably with the protease inhibitors, atazanavir and ritonavir, which are
potent inhibitors of the cytochrome P450 enzymes.<sup><xref rid="r09" ref-type="bibr">9</xref></sup><sup>,10</sup></p>
      <p>In conclusion, we stress the need for dermatologists to become familiar with these new
drugs and related mucocutaneous adverse effects, which are becoming increasingly
frequent in our practice. A multidisciplinary approach is essential for the appropriate
management of cases like the one reported.</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn fn-type="supported-by">
        <p>Financial Support: None.</p>
      </fn>
      <fn fn-type="other">
        <p><bold>How to cite this article:</bold> Pasin VP, Pereira AR, Carvalho KA, Paiva JMG,
Enokihara MMSS, Porro AM. New drugs, new challenges to dermatologists: mucocutaneous
ulcers secondary to everolimus. An Bras Dermatol. 2015;90 (3 Suppl 1):S165-7.</p>
      </fn>
      <fn fn-type="other" id="fn01">
        <label>*</label>
        <p>Work performed at the Universidade Federal de S&#xE3;o Paulo (UNIFESP) - S&#xE3;o Paulo,
Brazil.</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>References</title>
      <ref id="r01">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Peterson</surname>
              <given-names>ME</given-names>
            </name>
          </person-group>
          <article-title>Management of adverse events in patients with hormone
receptor-positive breast cancer treated with everolimus: observations from a phase
III clinical trial</article-title>
          <source>Support Care Cancer</source>
          <year>2013</year>
          <volume>21</volume>
          <fpage>2341</fpage>
          <lpage>2349</lpage>
          <pub-id pub-id-type="pmid">23686401</pub-id>
        </element-citation>
      </ref>
      <ref id="r02">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Martins</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>de Oliveira</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>Q</given-names>
            </name>
            <name>
              <surname>Sonis</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Gallottini</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>George</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>A review of oral toxicity associated with mTOR inhibitor therapy in
cancer patients</article-title>
          <source>Oral Oncol</source>
          <year>2013</year>
          <volume>49</volume>
          <fpage>293</fpage>
          <lpage>298</lpage>
          <pub-id pub-id-type="pmid">23312237</pub-id>
        </element-citation>
      </ref>
      <ref id="r03">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fert&#xE9;</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Paci</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Zizi</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Gonzales</surname>
              <given-names>DB</given-names>
            </name>
            <name>
              <surname>Goubar</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Gomez-Roca</surname>
              <given-names>C</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Natural history, management and pharmacokinetics of Everolimus
induced-oral ulcers: Insights into compliance issues</article-title>
          <source>Eur J Cancer</source>
          <year>2011</year>
          <volume>47</volume>
          <fpage>2249</fpage>
          <lpage>2255</lpage>
          <pub-id pub-id-type="pmid">21489779</pub-id>
        </element-citation>
      </ref>
      <ref id="r04">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Boers-Doets</surname>
              <given-names>CB</given-names>
            </name>
            <name>
              <surname>Epstein</surname>
              <given-names>JB</given-names>
            </name>
            <name>
              <surname>Raber-Durlacher</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Ouwerkerk</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Logan</surname>
              <given-names>RM</given-names>
            </name>
            <name>
              <surname>Brakenhoff</surname>
              <given-names>JA</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Oral Adverse Events Associated with Tyrosine Kinase and Mammalian
Target of Rapamycin Inhibitors in Renal Cell Carcinoma: A Structured Literature
Review</article-title>
          <source>Oncologist</source>
          <year>2012</year>
          <volume>17</volume>
          <fpage>135</fpage>
          <lpage>144</lpage>
          <pub-id pub-id-type="pmid">22207567</pub-id>
        </element-citation>
      </ref>
      <ref id="r05">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lee</surname>
              <given-names>WJ</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Chang</surname>
              <given-names>SE</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>MW</given-names>
            </name>
            <name>
              <surname>Kang</surname>
              <given-names>YK</given-names>
            </name>
            <name>
              <surname>Choi</surname>
              <given-names>JH</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Cutaneous adverse effects in patients treated with the multitargeted
kinase inhibitors sorafenib and sunitinib</article-title>
          <source>Br J Dermatol</source>
          <year>2009</year>
          <volume>161</volume>
          <fpage>1045</fpage>
          <lpage>1051</lpage>
          <pub-id pub-id-type="pmid">19558553</pub-id>
        </element-citation>
      </ref>
      <ref id="r06">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Soefje</surname>
              <given-names>SA</given-names>
            </name>
            <name>
              <surname>Karnad</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Brenner</surname>
              <given-names>AJ</given-names>
            </name>
          </person-group>
          <article-title>Common toxicities of mammalian target of rapamycin
inhibitors</article-title>
          <source>Target Oncol</source>
          <year>2011</year>
          <volume>6</volume>
          <fpage>125</fpage>
          <lpage>129</lpage>
          <pub-id pub-id-type="pmid">21499766</pub-id>
        </element-citation>
      </ref>
      <ref id="r07">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Campistol</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>de Fijter</surname>
              <given-names>JW</given-names>
            </name>
            <name>
              <surname>Flechner</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Langone</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Morelon</surname>
              <given-names>E</given-names>
            </name>
            <collab>Stockfleth E mTOR inhibitor-associated dermatologic and mucosal
problems</collab>
          </person-group>
          <article-title>Clin</article-title>
          <source>Transplant</source>
          <year>2010</year>
          <volume>24</volume>
          <fpage>149</fpage>
          <lpage>156</lpage>
        </element-citation>
      </ref>
      <ref id="r08">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gurk-Turner</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Manitpisitkul</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Cooper</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>A Comprehensive Review of Everolimus Clinical Reports: A New Mammalian
Target of Rapamycin Inhibitor</article-title>
          <source>Transplantation</source>
          <year>2012</year>
          <volume>94</volume>
          <fpage>659</fpage>
          <lpage>668</lpage>
          <pub-id pub-id-type="pmid">22986894</pub-id>
        </element-citation>
      </ref>
      <ref id="r09">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Busti</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Hall</surname>
              <given-names>RG</given-names>
            </name>
            <name>
              <surname>Margolis</surname>
              <given-names>DM</given-names>
            </name>
          </person-group>
          <article-title>Atazanavir for the treatment of human immunodeficiency virus
infection</article-title>
          <source>Pharmacotherapy</source>
          <year>2004</year>
          <volume>24</volume>
          <fpage>1732</fpage>
          <lpage>1747</lpage>
          <comment>Josephson F. Drug-drug interactions in the treatment of HIV infection: focus
on pharmacokinetic enhancement through CYP3A inhibition. J Intern Med.
2010;268:530-9.</comment>
          <pub-id pub-id-type="pmid">15585441</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
